Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 November, 2021 19:15 IST
Glenmark Pharmaceuticals receives USFDA approval for Clindamycin Phosphate Foam
Source: IRIS | 21 Sep, 2021, 01.28PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Glenmark Pharmaceuticals (Glenmark), a manufacturer of generic formulation products and API,  has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately USD 12 million.

Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of the company gained Rs 5.90, or 1.19%, to trade at  Rs 500.80.  The total volume of shares traded  was  137,181 at the BSE (12.05 p.m., Tuesday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Indiabulls Real Estate raises Rs 750 mn through NCDs - 25-Nov-2021 11:13
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer